EGFR and esophageal squamous cell carcinoma: The picture is less clear in other SCCs: preclinical studies showed superior activity of cetuximab in EGFR-amplified and overexpressing esophageal SCC (ESCC) xenografts [59], and EGFR-amplified and overexpressing lung SCC patients responded better to gefitinib [49] and cetuximab and chemotherapy [54,60,61] than their EGFRlow counterparts.